Vigabatrin and Insulin Sensitivity
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- NAFLD
- Obesity
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Participants will receive either vigabatrin or placeboMasking: Triple (Participant, Care Provider, Investigator)Masking Description: The pharmacist will know the treatments assigned to each participant.Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 60 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04321395
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Samuel Klein, MD Washington University School of Medicine